PPARA and cardiomyopathy: PPARα stimulation by the drug Bezafibrate has previously been shown to ameliorate the cardiomyopathy symptoms of TAZ knockdown mice, and is currently the subject of a clinical trial26–28, and therefore PPARα activating compounds are of clinical interest in this disease.